- page

Domain Therapeutics announces first patient dosed with DT-9081 in phase I clinical study in patients...

Domain Therapeutics strengthens Scientific Advisory Board with appointment of immuno-oncology expert...

Domain Therapeutics presents new data on its EP4R and CCR8 antagonists at 2022 SITC Annual Meeting

Domain Therapeutics to progress into clinical trials with its EP4R antagonist DT-9081 in solid tumor...

Domain Therapeutics to present new data on its EP4R and CCR8 antagonists at 2022 SITC Annual Meetin...

Domain Therapeutics receives a single digit multimillion development milestone payment from Merck fo...

Domain Therapeutics raises $42m Series A financing

Ono Enters into Collaboration Agreement with Domain Therapeutics and Université de Montréal for GP...